Opakalim
Bipolar Disorder
Biohaven Therapeutics Ltd.Small moleculePhase 2/3Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 53/ 100
- Competitive Position
- 73/ 100
Competitive context
60 Active assets in the Bipolar Disorder cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Asenapine Dr. Stavroula Rakitzi | Phase 4 | BBB |
Quetiapine First Affiliated Hospital of Zhejiang University | Phase 4 | BBB |
Escitalopram First Affiliated Hospital of Zhejiang University | Phase 4 | BBB |
Lamotrigine Johns Hopkins University | Phase 4 | BBB |
Lithium, Elemental University of Aarhus | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Opakalim is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →